Should I Buy EDSA? EDSA 2026 Analysis

Should You Buy Edesa Biotech Inc (EDSA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

6.220

1 Day change

12.68%

52 Week Range

9.370

Analysis Updated At

2026/04/10

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Edesa Biotech Inc (EDSA) is not a strong buy at this time for a beginner investor with a long-term strategy. The lack of positive financial growth, no significant trading trends, and absence of recent news or catalysts make this stock a hold rather than a buy.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 48.526, and moving averages are converging, suggesting no clear momentum. Key support is at 5.194, and resistance is at 6.383, with the stock currently trading near the pivot point of 5.788.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

The stock's financial performance is weak, with negative net income and EPS. Technical indicators suggest no clear upward momentum. No recent news or events to drive positive sentiment.

Financial Performance

In Q1 2026, revenue remained at 0 with no growth. Net income improved by 38.98% YoY but remains negative at -2,247,669. EPS dropped significantly by -41.67% YoY to -0.28. Gross margin is 0, showing no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

1 Analyst Rating

Wall Street analysts forecast EDSA stock price to fall

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 5.520

Low

Averages

High

Current: 5.520

Low

Averages

High

H.C. Wainwright

Yi Chen

initiated

AI Analysis

2025-06-27

Reason

H.C. Wainwright

Yi Chen

Price Target

AI Analysis

2025-06-27

initiated

Reason

H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech with a Buy rating and $5 price target. Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company's lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.

Lucid Capital

Dev Prasad

Buy

initiated

2025-05-23

Reason

Lucid Capital

Dev Prasad

Price Target

2025-05-23

initiated

Buy

Reason

Lucid Capital analyst Dev Prasad initiated coverage of Edesa Biotech with a Buy rating and $9 price target. The firm has a positive outlook on the company's lead clinical asset, EB06. EB06 is a first-in-class, fully human monoclonal antibody targeting CXCL10, in development for the treatment of moderate-to-severe non-segmental vitiligo, a chronic autoimmune skin disorder with high unmet medical need, the analyst tells investors in a research note. Lucid says the mechanism of action is well-supported by a strong biological rationale. Lucid views Edesa as an attractive long-term growth opportunity, with a first-in-class asset.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EDSA

Unlock Now

EDSA Should I Buy

EDSA Should I Buy

Should You Buy Edesa Biotech Inc (EDSA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch